

Dr. Jonathan Bell Appointed to Orthocell Advisory Board

- Globally recognised UK orthopaedic surgeon, Dr. Jonathan Bell, appointed to Orthocell's Medical and Scientific Advisory Board
- This strategic appointment underpins Orthocell's key opinion led commercialisation strategy of CelGro® platform technology in key markets
- Orthocell intends to accelerate orthopaedic development in the medium term and remains focused on driving market entry for dental bone and soft tissue repair in the near term

Perth, Australia; 25 June 2018: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce the appointment of Dr. Jonathan Bell to its Medical and Scientific Advisory Board (MSAB).

The appointment of UK orthopaedic surgeon, Dr. Bell follows the recent successful CelGro® tendon study results announced on 6 June 2018 and ensures Orthocell is well positioned to expand CelGro® indications into the orthopaedic field (including bone, tendon, nerve and cartilage regeneration procedures), whilst simultaneously executing its near term market entry plans for oral bone and soft tissue repair. Orthocell intends to leverage this appointment, clinical results and existing European approval for orthopaedic regulatory submissions in key regions including the US, Europe and Australia.

Orthocell Managing Director Paul Anderson said: "Dr. Bell is a globally recognised thought leader in orthopaedic surgery and his position on the MSAB compliments the recent appointment of experts in oral bone regeneration. Attracting highly regarded surgeons to join our MSAB is reflective of the high-quality collagen medical devices manufactured by Orthocell. This appointment represents another exciting milestone for the Company."

Dr. Bell is a widely respected Consultant Orthopaedic Surgeon specialising in sports injuries, ligament reconstruction, tendinopathy and degenerative conditions. Dr. Bell consults at high profile clinics such as Wimbledon clinics and New Victoria Hospital and is considered an expert in advanced joint preservation and joint replacement techniques. With his research dedicated to minimally invasive techniques, he is also vastly experienced with arthroscopic surgery and reconstruction of ligament injuries. A leader in his field, Dr. Bell has a wide range of experience treating all levels of sports people, from the occasional jogger to the professional athlete. Dr. Bell also regularly teaches in the UK and overseas.

Dr. Jonathan Bell said: "CelGro® is an innovative scaffold with key advantages over other products and supports high quality tissue repair. I am very excited to work collaboratively with the MSAB and Orthocell to establish CelGro® as the best in class scaffold for bone and soft tissue repair."

The appointment of Dr. Bell to Orthocell's MSAB represents a significant milestone in CelGro®'s pathway to market and follows the regulatory approval in Europe (CE Mark) and successful CelGro®



clinical study results. The Company has agreed to issue Dr. Bell 500,000 unlisted options each exercisable at \$0.34 expiring 3 years from the date of issue.

The Company remains focused on executing its strategic market entry plans for CelGro® in oral bone and soft tissue regeneration in key European target regions. Orthocell is also well positioned to execute its CelGro® orthopaedic market entry plans, with the initial focus on the preparation of regulatory submissions in key regions including US, Europe and Australia. CelGro® is the highest quality, best-in-class medical device for bone and soft tissue repair with a total addressable market estimated to be worth approximately >US\$2.6bn p.a.

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Investor enquiries

Joel Seah
Vesparum Capital

P: +61 3 8582 4800

E: orthocell@vesparum.com

Media enquiries

Haley Chartres
Hales² Communications

P: +61 423 139 163

E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell's portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

